RNAC
Selecta Biosciences Inc

7,770
Loading...
Loading...
News
all
press releases
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?
Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·3mo ago
News Placeholder
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
chainwire·4mo ago
News Placeholder
Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs
Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs...
Yahoo! Finance: News·1y ago
News Placeholder
What Makes Cartesian Therapeutics, Inc. a New Buy Stock
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in...
Benzinga·1y ago
News Placeholder
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the Company), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting...
Business Wire·1y ago
News Placeholder
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that recently reported...
Business Wire·1y ago
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Sets New 1-Year Low at $13.19
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report)'s stock price reached a new 52-week low on Friday . The stock traded as low as $13.19 and last traded at $14.69, with a volume of 14103...
Ticker Report·1y ago
News Placeholder
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to...
Business Wire·1y ago
News Placeholder
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the Company), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting...
Business Wire·1y ago

Latest RNAC News

View

Advertisement. Remove ads.

Advertisement. Remove ads.